+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Predictive and Prognostic significance of high-sensitivity modified Glasgow Prognostic Score (HS-mGPS) in advanced gastric cancer patients treated with neoadjuvant chemotherapy



Predictive and Prognostic significance of high-sensitivity modified Glasgow Prognostic Score (HS-mGPS) in advanced gastric cancer patients treated with neoadjuvant chemotherapy



Zhonghua Zhong Liu Za Zhi 39(3): 195-200



目的: 探讨高敏感格拉斯哥评分(HS-mGPS)对进展期胃癌患者新辅助化疗疗效和预后的预测作用。 方法: 117例进展期胃癌患者术前接受SOX方案(奥沙利铂+替吉奥)或mFOLFOX6方案(奥沙利铂+亚叶酸钙+氟尿嘧啶)新辅助化疗,根据C反应蛋白(CRP)和血清白蛋白(ALB)水平计算HS-mGPS,分析HS-mGPS与进展期胃癌患者临床病理特征的关系以及影响新辅助化疗胃癌患者预后的因素。 结果: 117例接受新辅助化疗的进展期胃癌患者中,ⅡB期43例,Ⅲ期60例,Ⅳ期14例。新辅助化疗后的临床有效率为61.5%(72/117),疾病控制率为88.0%(103/117),组织学反应率为91.5%(107/117),R0切除率为81.2%(95/117)。全组患者的中位无病生存时间(DFS)为21.0个月(95%CI为6.4~35.6个月),中位总生存时间(OS)为39.0个月(95%CI为21.4~56.6个月)。HS-mGPS与进展期胃癌患者的T分期、N分期、M分期、化疗疗效和组织学反应有关(均P<0.05)。单因素和多因素分析显示,HS-mGPS、N分期和R0切除是影响进展期胃癌患者中位DFS和OS的独立因素(均P<0.05)。 结论: HS-mGPS可用于预测胃癌新辅助化疗的疗效和预后。.

Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 060117571

Download citation: RISBibTeXText

PMID: 28316218


Related references

High-sensitivity modified Glasgow prognostic score (HS-mGPS) Is superior to the mGPS in esophageal cancer patients treated with chemoradiotherapy. Oncotarget 8(59): 99861-99870, 2017

The high-sensitivity modified Glasgow prognostic score is superior to the modified Glasgow prognostic score as a prognostic predictor in patients with resectable gastric cancer. Oncology 87(4): 205-214, 2014

Comparison of the Glasgow Prognostic Score (GPS) and the modified Glasgow Prognostic Score (mGPS) in evaluating the prognosis of patients with operable and inoperable non-small cell lung cancer. Journal of Cancer Research and Clinical Oncology 142(6): 1285-1297, 2017

The high-sensitivity modified Glasgow prognostic score is superior to the modified Glasgow prognostic score as a prognostic predictor for head and neck cancer. Oncotarget 9(97): 37008-37016, 2019

Does the modified Glasgow Prognostic Score (mGPS) have a prognostic role in esophageal cancer?. Journal of Surgical Oncology 113(7): 732-737, 2017

Prognostic significance of the modified Glasgow prognostic score in elderly patients with gastric cancer. Journal of Gastroenterology 49(6): 1040-1046, 2015

Onodera's prognostic nutritional index(PNI)and the modified Glasgow Prognostic Score(mGPS)in colorectal cancer surgery. Gan to Kagaku Ryoho. Cancer and ChemoTherapy 41(10): 1273-1275, 2014

Changes in modified Glasgow prognostic score after neoadjuvant chemotherapy is a prognostic factor in clinical stage II/III esophageal cancer. Diseases of the Esophagus 29(2): 146-151, 2016

The Glasgow prognostic score as a prognostic factor in patients with advanced non-small cell lung cancer treated with cisplatin-based first-line chemotherapy. Journal of ChemoTherapy 27(1): 35-39, 2015

Prognostic impact of the high-sensitivity modified Glasgow prognostic score in patients with resectable non-small cell lung cancer. Journal of Cancer Research and Therapeutics 12(2): 945-951, 2017

Improvement of high-sensitivity inflammation-based Glasgow prognostic score by gastrectomy is a favorable prognostic factor in patients with gastric cancer. Anticancer Research 34(10): 5695-5702, 2014

Prognostic Value of the Glasgow Prognostic Score or Modified Glasgow Prognostic Score for Patients with Colorectal Cancer Receiving Various Treatments: a Systematic Review and Meta-Analysis. Cellular Physiology and Biochemistry 51(3): 1237-1249, 2018

Role of Predictive Value of the Modified Glasgow Prognostic Score for Later-line Chemotherapy in Patients With Metastatic Colorectal Cancer. Clinical Colorectal Cancer 17(4): E687-E697, 2018

Validation of the modified Glasgow Prognostic Score (mGPS) in recurrent ovarian cancer (ROC) - Analysis of patients enrolled in the GCIG Symptom Benefit Study (SBS). Gynecologic Oncology 148(1): 36-41, 2017

Neutrophil count and the inflammation-based glasgow prognostic score predict survival in patients with advanced gastric cancer receiving first-line chemotherapy. Asian Pacific Journal of Cancer Prevention 15(2): 945-950, 2014